Emerson Electric
EMR
$150.34
-1.19%
Emerson Electric Co. is a global industrial technology leader that designs and manufactures automation software, valves, gauges, switches, and power tools, serving industries such as energy, chemical, and manufacturing. The company has transformed into a pure-play industrial automation player by divesting its climate technology and consumer businesses, positioning itself as a key enabler of factory automation and digital transformation. Currently, investor attention centers on Emerson's ability to sustain growth through its software and systems segment, margin expansion from its portfolio streamlining, and its strategic role in the broader industrial automation cycle. The stock has seen a strong recovery over the past year, reflecting optimism about its focused strategy and end-market resilience.…
EMR
Emerson Electric
$150.34
Related headlines
Investment Opinion: Should I buy EMR Today?
We rate Emerson as a Hold, reflecting a balanced risk/reward. The analyst consensus is 'Buy' with an average target of $171.81, implying a 12.4% upside, but the wide target range and modest growth warrant caution. The thesis is that Emerson's automation focus and margin expansion will drive EPS growth, but the current valuation already prices in much of this optimism.
Sign up to view all
EMR 12-Month Price Forecast
The AI model assesses Emerson as a neutral opportunity. The company has solid profitability and a clear strategic direction, but its growth is sluggish and the valuation is not cheap. The forward PE of 21.1x is reasonable if EPS growth materializes, but the risk of disappointment is high given the modest revenue growth. The stance would upgrade to bullish if revenue growth accelerates above 5% and the stock pulls back to a forward PE below 19x. Conversely, a downgrade to bearish would occur if revenue growth turns negative or margins compress below 18%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Emerson Electric's 12-month outlook, with a consensus price target around $171.81 and implied upside of +14.3% versus the current price.
Average Target
$171.81
0 analysts
Implied Upside
+14.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$104 - $205
Analyst target range
The target price range spans from a low of $104.00 to a high of $205.00, representing a wide spread of 97% from low to high, which signals high uncertainty about Emerson's future performance. The low target of $104 implies a potential downside of -32% from the current price, likely pricing in a severe industrial downturn or margin compression. The high target of $205 suggests an upside of +34%, assuming accelerating automation adoption and successful software growth. The wide range reflects divergent views on the cyclicality of Emerson's end markets and the sustainability of its margin expansion. Institutional ratings show a mix of Equal Weight and Outperform, with no recent upgrades or downgrades in the last few months, indicating a stable but not overly enthusiastic outlook.
Bulls vs Bears: EMR Investment Factors
Emerson presents a mixed picture: strong profitability, a clear strategic focus on automation, and solid cash flow are countered by sluggish revenue growth and a rich valuation. The bull case rests on the market rewarding Emerson's transformation and forward earnings growth, while the bear case highlights cyclical risks and the possibility that growth fails to justify the premium. Currently, the evidence slightly favors the bulls given the analyst consensus and forward PE, but the key tension is whether Emerson can accelerate organic growth to ~5%+ and expand margins further; if it does, the stock could re-rate higher, but if growth stagnates, the valuation premium could compress sharply.
Bullish
- Portfolio transformation to pure-play automation: Emerson has divested climate tech and consumer businesses to focus on industrial automation, a structural growth market. This strategic shift is reflected in its software and systems segment, which generated $1.503B in Q2 FY2026, a key driver of higher-margin recurring revenue.
- Strong profitability and margin expansion: Gross margin is robust at 52.8%, and operating margin reached 19.6% in Q2 FY2026, up from 19.4% a year ago. Net margin improved to 13.5% from 10.9% in the same quarter last year, indicating successful cost control and operational leverage.
- Solid free cash flow generation: TTM free cash flow stands at $3.115B, supporting a dividend yield of 1.6% and a payout ratio of 52%. This cash generation provides flexibility for debt reduction, share buybacks, and strategic acquisitions.
- Analyst consensus and upside potential: With a consensus rating of 'Buy' and an average target price of $171.81, the stock offers a 12.4% upside from the current price of $152.82. The high target of $205 implies a 34% potential gain, reflecting optimism about automation demand.
Bearish
- Modest revenue growth: Q2 FY2026 revenue grew only 2.9% YoY, decelerating from 4.2% in the prior quarter. This sluggish growth is below the typical industrial automation cycle and may indicate end-market softness or share losses.
- High valuation multiples: Trailing PE of 32.2x and EV/EBITDA of 17.8x are at a premium to historical averages and peers. The PEG ratio of 1.78 suggests the stock is not cheap relative to its growth rate, leaving little room for disappointment.
- Wide analyst target range signals uncertainty: The spread between the low ($104) and high ($205) targets is 97%, indicating significant disagreement about Emerson's future. The low target implies a 32% downside, reflecting risks of a severe industrial downturn or margin compression.
- Negative relative strength vs S&P 500: Over the past year, EMR gained 14.8% versus the S&P 500's 18.65%, underperforming by 3.8%. Over six months, relative strength is -4.1%, suggesting the stock is lagging the broader market despite its absolute gains.
EMR Technical Analysis
Emerson's stock is in a clear uptrend, with a 1-year price change of +14.8% and a 6-month change of +10.5%, though it has pulled back from its 52-week high of $166.35. As of September 4, 2026, the stock trades at $152.82, which is approximately 92% of its 52-week range (calculated as (152.82-122.64)/(166.35-122.64) = 69%), indicating it is in the upper half of its yearly range, closer to the highs than the lows. This positioning suggests strong momentum but also potential overextension, as the stock is only 8% below its high. The 52-week low of $122.64 was set in March 2026, and the stock has since rallied over 24% from that level, confirming a robust recovery trend.
Beta
1.23
1.23x market volatility
Max Drawdown
-23.7%
Largest decline past year
52-Week Range
$123-$166
Price range past year
Annual Return
+13.9%
Cumulative gain past year
| Period | EMR Return | S&P 500 |
|---|---|---|
| 1m | -5.3% | -1.4% |
| 3m | +5.8% | +3.3% |
| 6m | +13.7% | +15.1% |
| 1y | +13.9% | +17.2% |
| ytd | +10.7% | +11.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EMR Fundamental Analysis
Emerson's revenue growth has been modest but steady, with the most recent quarter (Q2 FY2026, ending March 31, 2026) reporting revenue of $4.562 billion, up 2.9% year-over-year. This growth is a slight deceleration from the prior quarter's 4.2% YoY increase (Q1 FY2026 revenue of $4.346 billion vs. $4.175 billion in Q1 FY2025), but it remains positive. The company's revenue segments show Intelligent Devices as the largest contributor at $2.512 billion, followed by Software and Systems at $1.503 billion, and Safety and Productivity at $0.547 billion, indicating a diversified portfolio with software as a key growth driver. The multi-quarter trend shows revenue fluctuating between $4.3-$4.9 billion over the past year, with no clear acceleration, suggesting a mature industrial cycle.
Quarterly Revenue
$4.6B
2026-03
Revenue YoY Growth
+2.9%
YoY Comparison
Gross Margin
53.1%
Latest Quarter
Free Cash Flow
$3.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EMR Overvalued?
Given Emerson's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 32.2x, while the forward PE is 21.1x, indicating the market expects significant earnings growth (a 34% forward earnings yield improvement). This gap implies that analysts anticipate a substantial increase in EPS, likely driven by margin expansion and operational leverage. The PEG ratio of 1.78 suggests that the stock is not excessively overvalued relative to its expected growth, but it is not a deep value either. Emerson's EV/EBITDA of 17.8x is also elevated, reflecting a premium for its automation exposure.
PE
32.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 16x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Emerson carries a moderate debt load with a debt-to-equity ratio of 0.68, and interest expenses of $110M in Q2 FY2026, which is manageable given operating income of $901M. However, the current ratio of 0.88 indicates potential liquidity pressure, as current liabilities exceed current assets. Revenue growth is sluggish at 2.9% YoY, and the company's reliance on continued margin expansion to meet forward EPS estimates (which imply a 34% earnings yield improvement) is a risk if cost inflation or pricing pressures emerge. Free cash flow of $3.1B is solid, but a significant portion is returned to shareholders (52% payout ratio), leaving limited buffer for unexpected downturns.
FAQ
The key risks are: (1) Cyclicality: Emerson's end markets (energy, chemical, manufacturing) are cyclical, and a downturn could hit revenue and margins. With a beta of 1.233, the stock is more volatile than the market. (2) Valuation risk: The stock trades at a premium (trailing PE 32.2x), and if growth disappoints, the multiple could compress, leading to a -20% or more drop. (3) Competition: Emerson faces intense competition from larger players like Siemens and ABB, which could pressure market share. (4) Execution risk: The company's transformation to a pure-play automation company depends on successful integration of acquisitions and software growth. The most severe risk is a global recession, which could push the stock to the analyst low target of $104, a 32% loss.
The 12-month forecast for EMR is moderately positive. The base case, with a 50% probability, sees the stock reaching $160-175, aligning with the analyst average target of $171.81. The bull case, with a 25% probability, targets $180-205, driven by accelerating automation demand and margin expansion. The bear case, also 25% probability, sees the stock falling to $104-130, if a recession hits. The most likely scenario is the base case, assuming revenue growth of 3-4% and stable margins. Investors should watch for earnings reports and macro indicators to adjust their expectations.
EMR is fairly valued to slightly overvalued based on current metrics. The trailing PE of 32.2x is above the market average, but the forward PE of 21.1x is more in line with industrial peers. The PEG ratio of 1.78 suggests the stock is not cheap relative to its expected growth. Compared to its own history, the forward PE is near the 5-year average, indicating the market is pricing in a return to normal earnings growth. The EV/EBITDA of 17.8x is also at a premium. Overall, the market expects Emerson to deliver strong earnings growth, and if it does, the valuation is justified; if not, the stock could see multiple compression.
EMR is a moderate buy, not a strong one. The analyst consensus is 'Buy' with an average target of $171.81, implying a 12.4% upside from the current price of $152.82. However, the stock's revenue growth is only 2.9% YoY, and the trailing PE of 32.2x is high. The forward PE of 21.1x is more reasonable, but it depends on significant EPS growth. For long-term investors who believe in the automation theme and are willing to tolerate cyclicality, EMR could be a good addition. For those seeking faster growth or lower valuation, other options may be better. The biggest downside risk is a -32% drop to the analyst low target of $104 if a recession hits.
EMR is more suitable for long-term investment, given its cyclical nature and moderate growth. The stock has a beta of 1.233, meaning it can be volatile in the short term, but over the long term, its focus on industrial automation and software should drive value. The dividend yield of 1.6% provides some income, and the payout ratio of 52% is sustainable. For short-term traders, the stock's movements are tied to quarterly earnings and macro data, offering opportunities but with higher risk. A minimum holding period of 3-5 years is recommended to ride out cyclical downturns and benefit from the automation trend.